Diabetes mellitus due to underlying condition with hyperosmolarity with coma
Methodology & AI Transparency ⓘ
Diabetes mellitus due to underlying condition with hyperosmolarity with coma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as E08.01, Diabetes mellitus due to underlying condition with hyperosmolarity with coma falls under Diabetes & Glucose management, where peripheral monofilament testing [Diabetes mellitus due to underlying condition with hyperosmolarity with coma E08.01] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry E08.01: Diabetes mellitus due to underlying condition with hyperosmolarity with coma is managed within Diabetes & Glucose.
- 3 Typical cash cost range: Differential triage of Diabetes mellitus due to underlying condition with hyperosmolarity with coma (E08.01) utilizes peripheral monofilament testing [Diabetes mellitus due to underlying condition with hyperosmolarity with coma E08.01].
- 4 Top reported side effects / signs: Longitudinal Diabetes mellitus due to underlying condition with hyperosmolarity with coma monitoring tracks Fasting Plasma Glucose [Diabetes mellitus due to underlying condition with hyperosmolarity with coma E08.01] toward 75 – 95 mg/dL (E08.01).
Ask our AI Specialists anything about Diabetes mellitus due to underlying condition with hyperosmolarity with coma
What Is Diabetes mellitus due to underlying condition with hyperosmolarity with coma?
Designated in federal medical registries as E08.01, Diabetes mellitus due to underlying condition with hyperosmolarity with coma falls under Diabetes & Glucose management, where peripheral monofilament testing [Diabetes mellitus due to underlying condition with hyperosmolarity with coma E08.01] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
In Diabetes mellitus due to underlying condition with hyperosmolarity with coma (E08.01), physiological disruption stems from renal SGLT2 glucose in Diabetes mellitus due to underlying condition with hyperosmolarity with coma (E08.01: hyper-reabsorption), informing Type 1 & Type 2 Diabetes protocols that track Fasting Insulin [Diabetes mellitus due to underlying condition with hyperosmolarity with coma E08.01] (3.0 – 7.0 uIU/mL (E08.01)).
Common Symptoms & Clinical Signs
- • Presentation of Diabetes mellitus due to underlying condition with hyperosmolarity with coma (E08.01): tingling or numbness in Diabetes mellitus due to underlying condition with hyperosmolarity with coma (E08.01: in toes and)
- • Secondary Diabetes mellitus due to underlying condition with hyperosmolarity with coma clinical sign: blurred vision fluctuations in Diabetes mellitus due to underlying condition with hyperosmolarity with coma (E08.01: or slower healing)
- • Symptom flares in Diabetes mellitus due to underlying condition with hyperosmolarity with coma correlating with Fasting Plasma Glucose [Diabetes mellitus due to underlying condition with hyperosmolarity with coma E08.01] deviation outside 75 – 95 mg/dL (E08.01)
- • Functional diabetes & glucose impact requiring peripheral monofilament testing [Diabetes mellitus due to underlying condition with hyperosmolarity with coma E08.01] evaluation (E08.01)
Diabetes mellitus due to underlying condition with hyperosmolarity with coma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E08.01 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Diabetes mellitus due to underlying condition with hyperosmolarity with coma E08.01] | 75 – 95 mg/dL (E08.01) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Diabetes mellitus due to underlying condition with hyperosmolarity with coma E08.01] | 3.0 – 7.0 uIU/mL (E08.01) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Diabetes mellitus due to underlying condition with hyperosmolarity with coma (E08.01: mg/dL)) | > 85% (E08.01) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Diabetes mellitus due to underlying condition with hyperosmolarity with coma
Treatment selection for Diabetes mellitus due to underlying condition with hyperosmolarity with coma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diabetes mellitus due to underlying condition with hyperosmolarity with coma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
Diabetes mellitus due to underlying condition with hyperosmolarity with coma Patient Community & “People Like Me” Threads
Filter Diabetes mellitus due to underlying condition with hyperosmolarity with coma community threads and patient logs by age, biological sex, dosage, and treatment duration.